Tedalinab is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. It exhibits significant functional selectivity for CB2 over CB1, making it a promising compound for various therapeutic applications.
- Potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist
- Exhibits greater than 4700-fold functional selectivity for CB2 over CB1
- Potential for neuropathic pain and osteoarthritis treatment